These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 9428984

  • 1. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin.
    Wildfeuer A, Seidl HP, Paule I, Haberreiter A.
    Arzneimittelforschung; 1997 Nov; 47(11):1257-63. PubMed ID: 9428984
    [Abstract] [Full Text] [Related]

  • 2. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.
    Wildfeuer A, Seidl HP, Paule I, Haberreiter A.
    Mycoses; 1998 Nov; 41(7-8):309-19. PubMed ID: 9861837
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis.
    Carrillo-Muñoz AJ, Giusiano G, Guarro J, Quindós G, Guardia C, del Valle O, Rodríguez V, Estivill D, Cárdenes CD.
    Int J Antimicrob Agents; 2007 Aug; 30(2):157-61. PubMed ID: 17555945
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
    Arredondo-García JL, Amábile-Cuevas CF, RedMic2 Study Group.
    J Infect Dev Ctries; 2009 Jun 01; 3(5):398-401. PubMed ID: 19759511
    [Abstract] [Full Text] [Related]

  • 9. In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole.
    Rudramurthy SM, Jatana M, Singh R, Chakrabarti A.
    Mycoses; 2013 Jan 01; 56(1):39-46. PubMed ID: 22519679
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
    Yamazaki T, Inagaki Y, Fujii T, Ohwada J, Tsukazaki M, Umeda I, Kobayashi K, Shimma N, Page MG, Arisawa M.
    Int J Antimicrob Agents; 2010 Oct 01; 36(4):324-31. PubMed ID: 20674282
    [Abstract] [Full Text] [Related]

  • 11. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
    Marco F, Pfaller MA, Messer SA, Jones RN.
    Med Mycol; 1998 Dec 01; 36(6):433-6. PubMed ID: 10206756
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
    Bueno JG, Martinez C, Zapata B, Sanclemente G, Gallego M, Mesa AC.
    Clin Exp Dermatol; 2010 Aug 01; 35(6):658-63. PubMed ID: 19874354
    [Abstract] [Full Text] [Related]

  • 14. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, Fu W, Colombo AL, Rodriguez-Noriega E, Global Antifungal Surveillance Study.
    J Clin Microbiol; 2007 Jun 01; 45(6):1735-45. PubMed ID: 17442797
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A.
    Rev Iberoam Micol; 2003 Dec 01; 20(4):121-36. PubMed ID: 15456349
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole.
    Pearce JW, Giuliano EA, Moore CP.
    Vet Ophthalmol; 2009 Dec 01; 12(5):318-24. PubMed ID: 19751493
    [Abstract] [Full Text] [Related]

  • 20. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
    Swinne D, Watelle M, Van der Flaes M, Nolard N.
    Mycoses; 2004 Jun 01; 47(5-6):177-83. PubMed ID: 15189180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.